Norden Group LLC Has $7.14 Million Position in Repligen Co. (NASDAQ:RGEN)

Norden Group LLC raised its stake in shares of Repligen Co. (NASDAQ:RGEN) by 1,711.6% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 38,805 shares of the biotechnology company’s stock after buying an additional 36,663 shares during the period. Norden Group LLC’s holdings in Repligen were worth $7,137,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Norges Bank acquired a new stake in shares of Repligen in the 4th quarter valued at $48,208,000. Artemis Investment Management LLP acquired a new stake in shares of Repligen in the 4th quarter valued at $22,552,000. American Century Companies Inc. lifted its stake in shares of Repligen by 97.5% in the 3rd quarter. American Century Companies Inc. now owns 217,900 shares of the biotechnology company’s stock valued at $34,648,000 after purchasing an additional 107,570 shares during the last quarter. Comerica Bank lifted its stake in shares of Repligen by 1,259.1% in the 3rd quarter. Comerica Bank now owns 115,929 shares of the biotechnology company’s stock valued at $18,434,000 after purchasing an additional 107,399 shares during the last quarter. Finally, Public Employees Retirement Association of Colorado lifted its stake in shares of Repligen by 448.0% in the 4th quarter. Public Employees Retirement Association of Colorado now owns 112,863 shares of the biotechnology company’s stock valued at $20,293,000 after purchasing an additional 92,268 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Repligen Stock Performance

NASDAQ:RGEN opened at $120.77 on Friday. The firm’s 50-day moving average is $148.16 and its 200-day moving average is $172.37. Repligen Co. has a 52-week low of $110.45 and a 52-week high of $211.13. The company has a debt-to-equity ratio of 0.26, a quick ratio of 5.24 and a current ratio of 6.35. The company has a market cap of $6.75 billion, a price-to-earnings ratio of 483.10, a PEG ratio of 4.04 and a beta of 0.95.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings data on Wednesday, May 1st. The biotechnology company reported $0.28 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.29 by ($0.01). Repligen had a return on equity of 3.95% and a net margin of 2.44%. The company had revenue of $151.31 million for the quarter, compared to the consensus estimate of $150.06 million. During the same quarter in the previous year, the firm posted $0.64 EPS. The business’s revenue for the quarter was down 17.1% compared to the same quarter last year. Equities research analysts anticipate that Repligen Co. will post 1.46 earnings per share for the current year.

Analysts Set New Price Targets

Several research firms recently issued reports on RGEN. JPMorgan Chase & Co. reduced their price objective on shares of Repligen from $230.00 to $200.00 and set an “overweight” rating for the company in a research note on Thursday, May 2nd. Deutsche Bank Aktiengesellschaft raised shares of Repligen from a “hold” rating to a “buy” rating and cut their target price for the stock from $180.00 to $155.00 in a research report on Wednesday, June 26th. Finally, Guggenheim initiated coverage on shares of Repligen in a research report on Tuesday, June 18th. They set a “neutral” rating for the company. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and nine have assigned a buy rating to the company’s stock. According to data from MarketBeat, Repligen presently has a consensus rating of “Moderate Buy” and an average target price of $193.00.

Insider Transactions at Repligen

In other Repligen news, Director Martin D. Madaus bought 1,615 shares of the stock in a transaction that occurred on Friday, June 14th. The shares were acquired at an average price of $124.94 per share, with a total value of $201,778.10. Following the completion of the purchase, the director now directly owns 4,613 shares in the company, valued at approximately $576,348.22. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Repligen news, CEO Anthony Hunt bought 2,000 shares of the stock in a transaction that occurred on Friday, June 14th. The shares were acquired at an average price of $124.08 per share, with a total value of $248,160.00. Following the completion of the purchase, the chief executive officer now directly owns 165,177 shares in the company, valued at approximately $20,495,162.16. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Martin D. Madaus bought 1,615 shares of the stock in a transaction that occurred on Friday, June 14th. The stock was acquired at an average cost of $124.94 per share, for a total transaction of $201,778.10. Following the purchase, the director now owns 4,613 shares of the company’s stock, valued at $576,348.22. The disclosure for this purchase can be found here. Insiders own 1.20% of the company’s stock.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.